Sun Pharma is n focus after Taro, its US arm, reports a 30 percent decline in net sales. In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities shared his readings and outlook on the same as well as on some other pharma stocks.
first published: Aug 9, 2017 10:21 am
A collection of the most-viewed Moneycontrol videos.
Live: Nifty extends gain to the second straight day but sees another weekly loss | Closing Bell
Live: Can Nifty extend gains and reclaim 26,000? | Opening Bell
FSS Simply Payments 2025 | AI in Payments: Building a Governance-First Future.
Live: Nifty reclaims 25,900, snaps 3-day losing streak; rupee falls to fresh low | Closing Bell
